75 patents
Page 4 of 4
Utility
ANTI-TMEM106B Antibodies and Methods of Use Thereof
28 Oct 20
The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal antibodies, antibody fragments, etc., that specifically bind a TMEM106B polypeptide, e.g., a mammalian TMEM106B or human TMEM106B, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
Arnon ROSENTHAL, Eric BROWN, Tina SCHWABE, Angie YEE, Herve RHINN
Filed: 20 Dec 18
Utility
Anti-Siglec-9 antibodies and methods of use thereof
12 Oct 20
The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a Siglec-9 protein, e.g., human Siglec-9 or a mammalian Siglec-9, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
Arnon Rosenthal, Kate Monroe, Seung-Joo Lee
Filed: 27 Oct 16
Utility
ANTI-TREM2 Antibodies and Methods of Use Thereof
7 Oct 20
The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a TREM2 protein, e.g., a mammalian TREM2 or human TREM2, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
Tina SCHWABE, Eric BROWN, Philip KONG, Ilaria TASSI, Seung-Joo LEE, Arnon ROSENTHAL, Robert PEJCHAL, Nels P. NIELSON
Filed: 29 Mar 20
Utility
ANTI-SIGLEC-7 Antibodies and Methods of Use Thereof
2 Sep 20
The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Siglec-7 protein, e.g., human Siglec-7 or a mammalian Siglec-7, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
Kate MONROE, Helen LAM, Arnon ROSENTHAL, Seung-Joo LEE, Francesca AVOGADRI-CONNORS, William MONTEITH
Filed: 13 Feb 20
Utility
Anti-sortilin Antibodies and Methods of Use Thereof
15 Jul 20
The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Sortilin protein, e.g., human Sortilin or a mammalian Sortilin, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
Arnon ROSENTHAL, Tina SCHWABE, Michael KURNELLAS
Filed: 12 Jan 20
Utility
Anti-CD33 antibodies and methods of use thereof
13 Jul 20
The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a CD33 protein, e.g., human CD33 or a mammalian CD33, and have improved and/or enhanced functional characteristics, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
Patricia Culp, Helen Lam, Arnon Rosenthal, Seung-Joo Lee, Nels P. Nielson, Robert Pejchal
Filed: 2 Aug 18
Utility
Anti-TREM2 antibodies and methods of use thereof
8 Jun 20
The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a TREM2 protein, e.g., a mammalian TREM2 or human TREM2, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
Tina Schwabe, Eric Brown, Philip Kong, Ilaria Tassi, Seung-Joo Lee, Arnon Rosenthal, Robert Pejchal, Nels P. Nielson
Filed: 2 Aug 18
Utility
Anti-TREM1 Antibodies and Methods of Use Thereof
29 Apr 20
The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind a TREM1 protein, e.g., a mammalian TREM1 or human TREM1, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
Andrew Pincetic, Arnon Rosenthal, Helen Lam, Francesca Avogadri-Connors, Seung-Joo Lee
Filed: 2 Mar 17
Utility
Anti-siglec-7 antibodies and methods of use thereof
16 Mar 20
The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Siglec-7 protein, e.g., human Siglec-7 or a mammalian Siglec-7, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
Kate Monroe, Helen Lam, Arnon Rosenthal, Seung-Joo Lee, Francesca Avogadri-Connors, William Monteith
Filed: 25 Aug 16
Utility
Anti-sortilin Antibodies and Methods of Use Thereof
22 Jan 20
The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, affinity-matured, humanized antibodies, antibody fragments, etc., that specifically bind a Sortilin protein, e.g., human Sortilin or mammalian Sortilin, and have improved and/or enhanced functional characteristics, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
Tina SCHWABE, Michael KURNELLAS, Arnon ROSENTHAL, Robert PEJCHAL, Anthony B. COOPER
Filed: 11 Jul 19
Utility
Anti-APOE4 Antigen-Binding Proteins and Methods of Use Thereof
4 Dec 19
The present disclosure generally relates to antigen-binding proteins (ABPs) that specifically bind to apolipoprotein E (ApoE), compositions comprising such ABPs, methods of using such ABPs, and methods of making such ABPs.
Arnon Rosenthal
Filed: 9 Jan 19
Utility
Anti-Sirpa Antibodies and Methods of Use Thereof
27 Nov 19
The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a SIRPA polypeptide, e.g., a mammalian SIRPA or human SIRPA, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
Andrew Pincetic, Wei-Hsien Ho, Patricia Culp, Arnon Rosenthal
Filed: 23 May 19
Utility
ANTI-TREM2 Antibodies and Methods of Use Thereof
30 Oct 19
The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind a TREM2 protein, e.g., a mammalian TREM2 or human TREM2, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
Tina SCHWABE, Francesca AVOGADRI-CONNORS, Helen LAM, Ilaria TASSI, Seung-Joo LEE, Arnon ROSENTHAL
Filed: 5 Oct 16
Utility
ANTI-TREM2 Antibodies and Methods of Use Thereof
16 Oct 19
The invention is generally directed to methods and compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind a TREM2 protein, e.g., a mammalian TREM2 and/or human TREM2.
Kate Monroe, Tina Schwabe, Francesca Avogadri-Connors, Ilaria Tassi, Helen Lam, Arnon Rosenthal
Filed: 10 Apr 19
Utility
Anti-sortilin antibodies and methods of use thereof
30 Sep 19
The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Sortilin protein, e.g., human Sortilin or a mammalian Sortilin, and use of such compostions in preventing, reducing risk, or treating an individual in need thereof.
Arnon Rosenthal, Tina Schwabe, Michael Kurnellas
Filed: 19 Aug 18